
## Full Spectrum of MASH/Liver Disease Solutions







Reduce impact of reader variability and capture drug effect in clinical trials

\*under review by EMA/FDA

#### MASH biopsy WSI




#### **Al-Assist Report:**

- Pathologist AI-Assisted ordinal MASH CRN scores
- · AI-alone ordinal MASH CRN scores

H&E Report			
	AIM-MASH	Pathologist	Final
Steatosis	2	2 🗸	2
Ballooning	1	2 🗸	1
Lob. Inflam.	1	3 🗴	3
	MT Don	ort	

MT Report			
	AIM-MASH	Pathologist	Final
Fibrosis	4	4 🗸	4

### **AIM** () MASH+1




Nuanced and deeper understanding of changes within CRN grades/stages

#### MASH biopsy WSI




#### **Feature Reports:**

- · AI-alone ordinal MASH CRN scores
- · AI-derived continuous MASH CRN scores
- Artifact model OC features



# Liver Explore'




Quantitative description of liver microarchitecture to uncover insights into drug MOA and beyond

#### Liver biopsy WSI (40X)



#### **Feature Reports:**

- >1000 quantitative features: tissue, cell (including nuclear features), lobular zones, & fibrosis subtypes
- Artifact model QC features



Central Pathology Services for Clinical Trials

10

Biopharma sponsors trusting PathAl as their central pathology lab >25,000

# of slides read through our central lab to date 2-7

Avg day TAT from sample receipt to site report Zero

Critical findings across all audits to date (8+)

